News
Drug and biotech news
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
40 stories
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Gazyva (Obinutuzumab), Genentech
Efficacy supplement 44. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA novel drug approval: Klygefa (Gefurulimab), Alexion Pharm
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis Orphan.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Imfinzi (Durvalumab), Astrazeneca Uk LTD
Efficacy supplement 59. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Zurzuvae (Zuranolone), Biogen
Efficacy supplement 4. Priority review.
- FDA approvalDrugs@FDANov 13, 2026FDA new use approved: Myqorzo (Aficamten), Cytokinetics
Efficacy supplement 2. Orphan.
- FDA approvalDrugs@FDANov 12, 2026FDA new approval: Pebrilzo (Pertuzumab), Biocon Biologics INC
- FDA approvalDrugs@FDANov 10, 2026FDA novel drug approval: Pimjetmi (Pimicotinib), Emd Serono
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- FDA approvalDrugs@FDANov 9, 2026FDA new approval: Oxderys (Doxorubicin Hydrochloride), Avyxa Holdings
- FDA approvalDrugs@FDANov 9, 2026FDA new approval: Multibic (Multibic), Fresenius Medical Care Renal Therapies Group LLC
- FDA approvalDrugs@FDANov 9, 2026FDA novel drug approval: Sunharbo (Asundexian), Bayer Healthcare
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack Priority review.
- FDA approvalDrugs@FDANov 5, 2026FDA new use approved: Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj), Janssen Biotech
Efficacy supplement 2. Priority review.
- FDA approvalDrugs@FDAOct 29, 2026FDA new approval: Axycis (Cisplatin), Avyxa Holdings
- FDA approvalDrugs@FDAOct 27, 2026FDA new approval: Lucamzi (Ranibizumab-Blrz), Xbrane Biopharma Ab
- FDA approvalDrugs@FDAOct 26, 2026FDA new use approved: Talzenna (Talazoparib Tosylate), Pfizer
Efficacy supplement 14. Priority review.
- FDA approvalDrugs@FDAOct 26, 2026FDA new use approved: Talzenna (Talazoparib Tosylate), Pfizer
Efficacy supplement 4. Priority review.
- FDA approvalDrugs@FDAOct 23, 2026FDA new use approved: Skyrizi (Risankizumab-Rzaa), Abbvie INC
Efficacy supplement 53. Orphan, Priority review.
- FDA approvalDrugs@FDAOct 23, 2026FDA new use approved: Awiqli Flextouch (Insulin Icodec), Novo Nordisk INC
Efficacy supplement 1. Priority review.
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Enzeevu (Aflibercept-Abzv), Sandoz INC
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Ahzantive (Aflibercept-Mrbb), Formycon AG
- FDA approvalDrugs@FDAOct 22, 2026FDA new approval: Pavblu (Aflibercept-Ayyh), Amgen INC
- FDA approvalDrugs@FDAOct 21, 2026FDA new use approved: Ultomiris (Ravulizumab-Cwvz), Alexion Pharm
Efficacy supplement 46. Orphan, Priority review.
- FDA approvalDrugs@FDAOct 20, 2026FDA novel drug approval: Hibsago (Bepirovirsen Sodium), Glaxosmithkline
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy Priority review.
- FDA approvalDrugs@FDAOct 19, 2026FDA new approval: Calrezdy (Calcium Chloride), Fresenius Medcl Care
- FDA approvalDrugs@FDAOct 19, 2026FDA new use approved: Jemperli (Dostarlimab-Gxly), Glaxosmithkline
Efficacy supplement 15. Priority review.
- FDA approvalDrugs@FDAOct 19, 2026FDA new approval: Cienby (Trisodium Citrate), Fresenius Medcl Care
- FDA approvalDrugs@FDAOct 16, 2026FDA new use approved: Ayvakit (Avapritinib), Blueprint Medicines
Efficacy supplement 21. Orphan.
- FDA approvalDrugs@FDAOct 16, 2026FDA new approval: Brytly (Apraclonidine Hydrochloride), Alcon Labs INC
- FDA approvalDrugs@FDAOct 16, 2026FDA new approval: Yulzety (Rivaroxaban), Rosemont Pharms
- FDA approvalDrugs@FDAOct 16, 2026FDA new use approved: Keytruda (Pembrolizumab), Merck Sharp Dohme
Efficacy supplement 191. Orphan.
- FDA approvalDrugs@FDAOct 15, 2026FDA new approval: Evoxac (Cevimeline Hydrochloride), Cosette
- FDA approvalDrugs@FDAOct 15, 2026FDA new use approved: Enspryng (Satralizumab), Genentech
Efficacy supplement 8. Priority review.
- FDA approvalDrugs@FDAOct 15, 2026FDA new use approved: Zilbrysq (Zilucoplan Sodium), Ucb INC
Efficacy supplement 15. Orphan.
- FDA approvalDrugs@FDAOct 9, 2026FDA new approval: Isovue Readi (Iopamidol), Bracco
- FDA approvalDrugs@FDAOct 9, 2026FDA new use approved: Repatha (Evolocumab), Amgen INC
Efficacy supplement 47. Orphan.
- FDA approvalDrugs@FDAOct 9, 2026FDA novel drug approval: Hovilpri (Pritelivir Mesylate), Aicuris Anti-Infect
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies Priority review.
- FDA approvalDrugs@FDAOct 8, 2026FDA new use approved: Tecentriq (Atezolizumab), Genentech INC
Efficacy supplement 65. Priority review.
- FDA approvalDrugs@FDAOct 8, 2026FDA new approval: Weltruza (Olanzapine), Teva
- FDA approvalDrugs@FDAOct 8, 2026FDA new approval: Breztri Aerosphere (Budesonide, Formoterol Fumarate, Glycopyrrolate), Astrazeneca Ab
- FDA approvalDrugs@FDAOct 8, 2026FDA new use approved: Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs), Genentech INC
Efficacy supplement 11. Priority review.
- FDA approvalDrugs@FDAOct 7, 2026FDA new use approved: Tukysa (Tucatinib), Seagen
Efficacy supplement 10. Orphan.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.